Abstract:Background: In recent years, the time of blood glucose within the target range is a new research hotspot in blood glucose management. TIR is expected to be a novel indicator for evaluating the efficacy of glycemic control and predicting diabetic complications. However, its relationship with diabetic complications has not been fully elucidated. Objective: To explore the relationship between time in range (TIR) and glycosylated hemoglobin (HbA1C) through the information big data management platform. Possible association between TIR and diabetic microvascular complications (retinopathy, nephropathy, and neuropathy) was investigated, attempting to provide theoretical basis for the clinical application of TIR and to explore the TIR control scope suitable for diabetic patients. Methods: A total of 5,644 type 2 diabetic patients hospitalized in the Department of Endocrinology, the Second Affiliated Hospital of Nanchang University, were selected from April 2017 to June 2020. Fingertip capillary blood glucose monitoring (FCGM) was monitored for a total of 455,664 times, and patients who are nondiabetic, pregnant, or with diabetic ketosis were excluded. Patients with 7 blood glucose points monitored for at least three consecutive days were selected as subjects in the study. 1,895 males and 1,513 females with diabetes were included, with an average age of (59.74 ± 13.40) years old and an average course of disease of 8.28 ± 7.11 years. The proportion of time in range (TIR) (70∼180 mg/dl) within the target range and the correlation between TIR and HbA1C were analyzed, as well as the relationship between TIR and the risk of diabetic complications. Results: (1) The average of TIR and HbA1C was 49.65 ± 23.36% and 8.92 ± 2.49%, respectively, and was linearly correlated. With the decrease of TIR, HbA1C increased significantly, and the difference was statistically significant (P < 0.01, R 2 = 0.458). The correlation coefficient of mean TIR with mean HbA1C was -0.626. (2) There were 836 patients diagnosed with diabetic nephropathy (DN). The difference of TIR value between DN and non-DN was significant (T = 2.250, P < 0.05). Risk assessment showed the lower the TIR was, the higher the risk of DN was. TIR less than 40% was a risk factor for DN (OR = 1.249, 95% CI: 0.915-1.375). (3) There were 1,296 patients diagnosed with diabetic peripheral neuropathy (DPN). The difference of TIR value between DPN and non-DPN was significant (T = 3.844, P < 0.01). TIR value less than 70% was a risk factor for DPN (OR = 1.030, 95% CI: 0.769-1.379). (4) There were 2,077 patients diagnosed with diabetic retinopathy (DR). The difference of TIR value between DPN and non-DPN was significant (T = 3.608, P < 0.01). TIR value less than 50% was a risk factor for DR (OR = 1.092, 95% CI: 0.898-1.264). Summary. TIR may serve as a reference index for short-term blood glucose control, strongly reflecting the clinical blood glucose regulation and predicting the risk of diabetic microvascular complications.

Time in tight range: A key metric for optimal glucose control in the era of advanced diabetes technologies and therapeutics

Author Response for "time in Tight Range: A Key Metric for Optimal Glucose Control in the Era of Advanced Diabetes Technologies and Therapeutics"

Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes

Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control

Research progress in the application of time in range: more than a percentage

Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems

Comparison of Multiple Cut Points for Time in Range in Relation to Risk of Abnormal Carotid Intima-Media Thickness and Diabetic Retinopathy

Is there a target value for time in tight range for individuals with type 1 diabetes on MDI? Data from masked CGM

The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c

Evaluating the Role of Time in Range As a Glycemic Target During Short-Term Intensive Insulin Therapy in Patients with Newly Diagnosed Type 2 Diabetes

The Correlation between Time in Range and Diabetic Microvascular Complications Utilizing Information Management Platform

Time in Range, As a Novel Metric of Glycemic Control, is Reversely Associated with Presence of Diabetic Cardiovascular Autonomic Neuropathy Independent of HbA1c in Chinese Type 2 Diabetes

Time in Range Analysis in Automated Insulin Delivery Era: Should Day and Nighttime Targets be the Same?

Association between time in range, a novel measurement of glycemic control and islet secretory function in chinese patients with type 2 diabetes mellitus—An observational study

Assessing the feasibility of time in tight range (TITR) targets with advanced hybrid closed loop (AHCL) use in children and adolescents: A single‐centre real‐world study

Time In Tight Range in children and adolescents with type 1 diabetes: A cross‐sectional observational single centre study evaluating efficacy of new advanced technologies

'We're taught green is good': Perspectives on time in range and time in tight range from youth with type 1 diabetes, and parents of youth with type 1 diabetes

Utility of time in tight range (TITR) in evaluating metabolic control in pediatric and adult patients with type 1 diabetes in treatment with advanced hybrid closed-loop systems

The interdependence of targets for continuous glucose monitoring outcomes in type 1 diabetes with automated insulin delivery

[The Appropriate Cut-off Point of Time in Range (TIR) for Evaluating Glucose Control in Type 2 Diabetes Mellitus].

1026-P: Time in Range in Relation to Diabetic Kidney Disease in Type 2 Diabetes—A Cross-Sectional Study in a Chinese Population